LeMaitre Vascular (NASDAQ:LMAT) Issues Earnings Results

LeMaitre Vascular (NASDAQ:LMAT) announced its quarterly earnings results on Thursday. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05, Briefing.com reports. LeMaitre Vascular had a return on equity of 13.39% and a net margin of 19.40%. The company had revenue of $54.82 million during the quarter, compared to analyst estimates of $53.50 million. During the same quarter in the previous year, the firm posted $0.33 EPS. The firm’s quarterly revenue was up 15.6% on a year-over-year basis.

LeMaitre Vascular Stock Up 7.3 %

Shares of LeMaitre Vascular stock opened at $94.88 on Friday. The stock’s fifty day moving average is $89.59 and its 200-day moving average is $83.11. The firm has a market capitalization of $2.13 billion, a PE ratio of 51.85, a price-to-earnings-growth ratio of 2.32 and a beta of 0.89. LeMaitre Vascular has a 12-month low of $45.96 and a 12-month high of $101.67.

LeMaitre Vascular Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 5th. Stockholders of record on Thursday, November 21st will be given a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.67%. The ex-dividend date is Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 34.97%.

Analyst Upgrades and Downgrades

LMAT has been the topic of a number of research reports. JMP Securities boosted their price objective on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 20th. Barrington Research boosted their price objective on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research note on Friday. Cantor Fitzgerald initiated coverage on LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price objective on the stock. StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Tuesday, August 27th. Finally, Oppenheimer reissued an “outperform” rating and issued a $93.00 price objective (up previously from $90.00) on shares of LeMaitre Vascular in a research note on Friday. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $94.57.

Insider Transactions at LeMaitre Vascular

In other news, Director David B. Roberts sold 3,063 shares of LeMaitre Vascular stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total transaction of $251,380.41. Following the transaction, the director now owns 14,114 shares in the company, valued at approximately $1,158,335.98. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 10.79% of the stock is owned by insiders.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.